The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A Narrative Review

Abstract

The purpose of this review is to evaluate the possible benefits of using psilocybin (C12H17N2O4P), a naturally occurring psychoactive compound found in certain species of mushrooms, in the treatment of multiple forms of mental illness and substance use disorders, either as monotherapy or in conjunction with traditional psychiatric medications. The compound has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, which are located throughout the cerebral cortex and thalamus. A comprehensive search of electronic databases was conducted, identifying studies that assessed pharmacokinetics, therapeutic efficacy, and the safety profile of psilocybin in the treatment of depression, anxiety, and addiction disorders. The findings are promising and support its efficacy, with decreased symptoms across multiple psychiatric disorders and a rapid onset of action. Significant research barriers remain, however, including methodological limitations, regulatory constraints, and limited population diversity in the clinical trials conducted to date. United States (US) federal funding for the study of psilocybin as a possible therapeutic option has not been approved to date. Biosynthetic production of the compound and enhanced integration into psychotherapy will be necessary to ensure scalability, safety, and accessibility. Continued research is essential to evaluate and refine its therapeutic applications on a larger scale.